Purpose To compare the efficacy and safety of 5-Aminolevulinic Acid Photodynamic Therapy (5-ALA-PDT) and Loop Electrosurgical Excision Procedure (LEEP) in the treatment of cervical high grade squamous intraepithelial lesions (HSIL). Methods The data of 116 patients with pathologically diagnosed cervical HSIL in Hangzhou First People’s Hospital from January 2020 to June 2023 were retrospectively analyzed. According to the treatment methods, they were divided into 5-ALA-PDT group (50 cases) and LEEP group (66 cases). The patients were followed up at 3 months, 6 months, and 12 months after treatment. The clinical data of the two groups were compared. Results There were no significant differences in baseline data between the two groups of patients (P > 0.05). At 12-month follow-up the complete remission (CR) rate of LEEP group and 5-ALA-PDT group was 93.94% (62/66) and 86.00% (43/50) (P = 0.260), respectively. The HPV clearance rate of LEEP group and 5-ALA-PDT group was 66.67% (44/66) and 80.00% (40/50) (P = 0.112), respectively. Multivariate analysis revealed that endocervical canal involvement was a significant risk factor for 5-ALA-PDT failure (OR = 27.35, 95% CI: 3.512–43.390, P = 0.012) and persistent HPV infection (OR = 8.013, 95% CI: 2.045–36.901, P = 0.011). In terms of adverse reactions, most of the reactions in 5-ALA-PDT group were mild local reactions that could be relieved within one week. The proportion of bleeding and cervical scar formation was higher in patients in the LEEP group (P < 0.05). Conclusion 5-ALA-PDT and LEEP exhibit potential similarity in efficacy in the treatment of cervical HSIL, but the former has milder adverse reactions. The involvement of the endocervical canal is a significant risk factor for both 5-ALA-PDT failure and persistent HPV infection.
Cervical cancer remains a major global health burden, particularly in settings with limited access to screening and human papillomavirus (HPV) vaccination. Although surgery and chemoradiation can achieve high cure rates in early-stage disease, outcomes for persistent, recurrent, or metastatic disease remain poor, highlighting the need for more effective and individualized systemic therapies. Immune checkpoint inhibitors have become integral to the treatment landscape, yet clinical benefit is modest for many patients and biomarker guidance remains imperfect. In this review, we define “precision management” as the biomarker- and microenvironment-informed selection of immunotherapy-based regimens across disease settings, coupled with rational combination design to overcome resistance. We synthesize cervical cancer–specific immune biology, including HPV-mediated immune evasion, and critically compare pivotal positive and negative clinical trials to explain why certain combinations succeed or fail. Finally, we discuss translational enablers—robust biomarkers, optimized delivery platforms, and functional models such as organoids—that may accelerate evidence-based personalization of immunotherapy in cervical cancer.